PRICING MISSTEP Novo also drew backlash from insurers, doctors and patients for launching Wegovy in the U.S. at more than $1,300 per month, about $350 more than Ozempic.

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, and valuation discounts.

Deep Apple discovers drug candidates using its AI-based platform that screens virtual libraries of billions of compounds to cut drug discovery time, the company said. Under the deal, Novo will ...

Novo has agreed to pay up to $812 million, including an upfront payment, research costs and milestones, for a global license to small molecules aimed at a GPCR target that isn’t an incretin. GLP ...

A persistent underground fire at the illegal Krupačke stijene landfill in the Krupac area is sending toxic smoke across western parts of the city.

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I reiterate buy rating on NVO stock.

See the latest Novo Nordisk AS ADR stock price (NVO:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

In January, Novo recorded 22% weight loss in people who received weekly amycretin injections for 36 weeks in a phase 1b/2a study. The company didn’t mention whether weight loss appeared to ...

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) both jumped 0 ...

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...